Clinical significance of micrometastasis of stage II colorectal cancer. A prospective multicenter trial

Clinical significance of micrometastasis of stage II colorectal cancer. A prospective multicenter trial - Prospective study of micrometastasis in stage II CRC (MCSGO-01)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000185

Enrollment

350

Registered

2006-01-01

Start date

2001-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage II colorectal cancer

Interventions

Randomization in micrometastasis positive cases HCHU 300mg for 1 year Randomization in micrometastasis positive cases No therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Curatively resected Stage II colorectal cancer With informed consent,performance status is 0-2.

Exclusion criteria

Exclusion criteria: simultaneous or metachrounous cancers multiple cancer lesions

Design outcomes

Primary

Measure	Time frame
3 year-disease free survival when stratified by presense or absence of micrometastasis	—

Secondary

Measure	Time frame
5 year-overall survival when stratified by presense or absence of micrometastasis	—

Countries

Japan

Contacts

Public ContactHirofumi Yamamoto

MCSGO(Multicenter Clinical Study Group of Osaka, Colorectal Cancer Division) Coordinating Office

hyamamoto@gesurg.med.osaka-u.ac.jp06-6879-3251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026